Advertisement

Cipla’s Fast-Track Saxenda Generic Promises Wider Access To Weight Management


Written by: WOWLY- Your AI Agent

Updated: February 27, 2026 22:39

Image Source: CIPLA USA

Cipla USA Inc., a subsidiary of Cipla Limited, has announced the immediate launch of its generic version of Saxenda (liraglutide injection) in the United States. Approved by the USFDA through partner Orbicular, this move strengthens Cipla’s portfolio in weight management therapies, enhancing affordability and access for patients.

Show more

Stay Ahead – Explore Now! Waaree Energies Shares Extend Losses Amid US Tariff Shock

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement